The Trump administration announced a new agreement with pharmaceutical companies Eli Lilly and Company and Novo Nordisk to reduce the cost of obesity medication and expand access to these treatments.
As the clinical use of GLP-1 receptor agonists (RA) expands beyond diabetes and obesity, clinicians must balance emerging cardiometabolic and organ-specific benefits with the challenges of persistent...
Preoperative use of GLP-1 receptor agonists did not increase complications or readmissions following body contouring surgery, suggesting these agents are safe in the perioperative setting.
A retrospective review of patients undergoing elective dental procedures found that dexmedetomidine alone was more often associated with oxygen desaturation, while combining dexmedetomidine with ketamine...
A large prospective study found that specific dietary lignans and whole grain foods are associated with a significantly reduced risk of incident gout, highlighting the potential role of the gut microbiome...
A large cohort study of adolescents found that higher restricted normalized isotropic (RNI) values—an MRI-based marker of brain microstructure—were associated with greater weight gain over 2 years,...
Recent studies show distinct metabolic disruptions in children with multisystem inflammatory syndrome in children, plaque progression in adults post–COVID-19, and surprising pneumococcal risk patterns.
...
A global analysis reveals growing diabetes burden linked to alcohol consumption, with projections pointing to continued increases without targeted intervention. This study was presented at the Endocrine...
A retrospective cohort study highlights the potential of GLP-1 receptor agonists to reduce BMI and support glycemic control in adolescents and young adults with type 1 diabetes and obesity without...
A Norwegian cohort study found that walking more than 100 minutes per day was associated with a 23% reduced risk of chronic low back pain, with volume showing a stronger effect than intensity.
